4.4 Review

Questions regarding the safety and duration of immunity following live yellow fever vaccination

期刊

EXPERT REVIEW OF VACCINES
卷 15, 期 12, 页码 1519-1533

出版社

TAYLOR & FRANCIS LTD
DOI: 10.1080/14760584.2016.1198259

关键词

Yellow fever virus; neurotropic; viscerotropic; vaccination; flaviviruses; antibody duration; immunity

资金

  1. National Institute of Allergy and Infectious Diseases [R44 AI079898, R01 AI098723]
  2. Oregon National Primate Research Center [8P51 OD011092-53]

向作者/读者索取更多资源

Introduction: The World Health Organization (WHO) and other health agencies have concluded that yellow fever booster vaccination is unnecessary since a single dose of vaccine confers lifelong immunity. Areas covered: We reviewed the clinical studies cited by health authorities in their investigation of both the safety profile and duration of immunity for the YFV-17D vaccine and examined the position that booster vaccination is no longer needed. We found that antiviral immunity may be lost in 1-in-3 to 1-in-5 individuals within 5 to 10 years after a single vaccination and that children may be at greater risk for primary vaccine failure. The safety profile of YFV-17D was compared to other licensed vaccines including oral polio vaccine (OPV) and the rotavirus vaccine, RotaShield, which have subsequently been withdrawn from the US and world market, respectively. Expert commentary: Based on these results and recent epidemiological data on vaccine failures (particularly evident at >10 years after vaccination), we believe that current recommendations to no longer administer YFV-17D booster vaccination be carefully re-evaluated, and that further development of safer vaccine approaches should be considered.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据